Aquestive Therapeutics's major customers
Indivor accounted for 73% of Aquestive Therapeutics's revenue in FY 2025, up from 62% a year earlier.
Get an email when Aquestive Therapeutics's customer concentration changes
When a new annual report adds a 10% customer, drops one, or moves a share by 5 points or more, you get the change and the filing link. Up to 10 companies per address, no account, unsubscribe with one click.
Major customers of Aquestive Therapeutics
Customers that Aquestive Therapeutics named in its annual report as 10% or more of revenue. A missing year means the customer was below that line or not named.
| Customer | Share of revenue | Change vs prior year | History | Latest filing |
|---|---|---|---|---|
| Indivor | 73% | ▲ from 62% | 3 years | FY 2025 · filed 4 Mar 2026 |
| Haisco | 17% | ▲ from 12% | 2 years | FY 2025 · filed 4 Mar 2026 |
Formerly disclosed
| Customer | Share of revenue | Change vs prior year | History | Latest filing |
|---|---|---|---|---|
| Sunovion | 26% | last FY 2020 | 1 year | FY 2020 · filed 8 Mar 2022 |
About this data
US-listed companies must disclose revenue from any single customer that reaches 10% of their total (ASC 280). ShadowGraph reads these disclosures from the XBRL data of every 10-K and 20-F we scan, keeps one value per fiscal year (restatements replace earlier values) and links each number to its filing. Companies that describe a customer only as "Customer A" are not listed by name. Figures are as reported; nothing here is investment advice.
All companies · Latest dependency shifts · Bulk data and API